Morgan Stanley
CRVO icon

Morgan Stanley’s CervoMed CRVO Stock Holding History

Morgan Stanley’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Sell
12,699
-727,193
-98% -$2.56M ﹤0.01% 6591
2026
Q1 		$2.92M Buy
739,892
+265,398
+56% +$1.39M ﹤0.01% 4489
2025
Q4 		$3.75M Buy
474,494
+60,457
+15% +$486K ﹤0.01% 4396
2025
Q3 		$3.35M Buy
414,037
+38,747
+10% +$332K ﹤0.01% 4453
2025
Q2 		$2.36M Buy
375,290
+238,233
+174% +$2.03M ﹤0.01% 4594
2025
Q1 		$1.25M Buy
137,057
+86,429
+171% +$329K ﹤0.01% 4897
2024
Q4 		$118K Buy
50,628
+5,525
+12% +$53.7K ﹤0.01% 5991
2024
Q3 		$659K Buy
45,103
+37,436
+488% +$580K ﹤0.01% 5272
2024
Q2 		$131K Buy
7,667
+7,665
+383,250% +$168K ﹤0.01% 5863
2024
Q1 		$47 Hold
2
– – ﹤0.01% 7503
2023
Q4 		$15 Sell
2
-362
-99% -$3.13K ﹤0.01% 7734
2023
Q3 		$1.68K Sell
364
-1
-0.3% -$5 ﹤0.01% 7157
2023
Q2 		$1.83K Hold
365
– – ﹤0.01% 7210
2023
Q1 		$2.27K Hold
365
– – ﹤0.01% 7219
2022
Q4 		$2.77K Hold
365
– – ﹤0.01% 7293
2022
Q3 		$3K Hold
365
– – ﹤0.01% 7373
2022
Q2 		$4K Hold
365
– – ﹤0.01% 7442
2022
Q1 		$7K Hold
365
– – ﹤0.01% 7496
2021
Q4 		$8K Buy
365
+266
+269% +$8.32K ﹤0.01% 7526
2021
Q3 		$4K Hold
99
– – ﹤0.01% 7536
2021
Q2 		$5K Sell
99
-34
-26% -$1.88K ﹤0.01% 7372
2021
Q1 		$9K Buy
133
+120
+923% +$10.1K ﹤0.01% 6967
2020
Q4 		$1K Buy
+13
New +$761 ﹤0.01% 6940
2020
Q2 		– Hold
0
– – – 6617
2020
Q1 		– Hold
0
– – – 6582
2019
Q4 		– Sell
-13
Closed -$795 – 6664
2019
Q3 		$2K Buy
13
+10
+333% +$1.61K ﹤0.01% 6472
2019
Q2 		$1K Buy
+3
New +$809 ﹤0.01% 6527
2017
Q3 		– Hold
0
– – – 6541
2017
Q2 		– Sell
-11
Closed -$35.4K – 6595
2017
Q1 		$50K Buy
+11
New +$47.2K ﹤0.01% 5826

Other funds holding CRVO

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Morgan Stanley's CRVO Position: Q2 2026 in Review

Morgan Stanley reduced its CervoMed (CRVO) stake by 98% in Q2 2026, selling an estimated $2.56M and leaving 12,699 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6591.

Morgan Stanley first reported a position in CRVO in Q1 2017 and has held it in 26 quarters since. The position peaked at $3.75M in Q4 2025. 37 funds tracked by Wall St. Rank hold CRVO as of Q2 2026.

  • Morgan Stanley held 12,699 shares of CervoMed worth $39.4K as of Q2 2026.
  • Morgan Stanley sold 727,193 CervoMed shares in Q2 2026, an estimated $2.56M.
  • CervoMed made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6591 holding.
  • Morgan Stanley first reported a position in CervoMed in Q1 2017 and has held it in 26 quarters since.
  • Morgan Stanley's CervoMed position peaked at $3.75M in Q4 2025.
  • 37 funds tracked by Wall St. Rank held CervoMed as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.